癌症中 RNA 剪接的失调和治疗靶标。
Dysregulation and therapeutic targeting of RNA splicing in cancer.
机构信息
Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Nat Cancer. 2022 May;3(5):536-546. doi: 10.1038/s43018-022-00384-z. Epub 2022 May 27.
Abstract
High-throughput sequencing and functional characterization of the cancer transcriptome have uncovered cancer-specific dysregulation of RNA splicing across a variety of cancers. Alterations in the cancer genome and dysregulation of RNA splicing factors lead to missplicing, splicing alteration-dependent gene expression and, in some cases, generation of novel splicing-derived proteins. Here, we review recent advances in our understanding of aberrant splicing in cancer pathogenesis and present strategies to harness cancer-specific aberrant splicing for therapeutic intent.
摘要
高通量测序和癌症转录组的功能特征分析揭示了多种癌症中 RNA 剪接的特异性失调。癌症基因组的改变和 RNA 剪接因子的失调导致错配剪接、依赖剪接改变的基因表达，在某些情况下还会产生新的剪接衍生蛋白。在这里，我们回顾了近年来对癌症发病机制中异常剪接的理解的进展，并提出了利用癌症特异性异常剪接进行治疗的策略。
相似文献
1
Dysregulation and therapeutic targeting of RNA splicing in cancer.癌症中 RNA 剪接的失调和治疗靶标。
Nat Cancer. 2022 May;3(5):536-546. doi: 10.1038/s43018-022-00384-z. Epub 2022 May 27.
2
Aberrant RNA splicing and therapeutic opportunities in cancers.癌症中异常的 RNA 剪接和治疗机会。
Cancer Sci. 2022 Feb;113(2):373-381. doi: 10.1111/cas.15213. Epub 2021 Nov 30.
3
Therapeutic Targeting of RNA Splicing in Cancer.癌症中 RNA 剪接的治疗靶向。
Genes (Basel). 2023 Jun 29;14(7):1378. doi: 10.3390/genes14071378.
4
RNA Splicing and Cancer.RNA 剪接与癌症。
Trends Cancer. 2020 Aug;6(8):631-644. doi: 10.1016/j.trecan.2020.04.011. Epub 2020 May 17.
5
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.癌症中的异常RNA剪接；剪接因子基因的表达变化和驱动突变
Oncogene. 2016 May 12;35(19):2413-27. doi: 10.1038/onc.2015.318. Epub 2015 Aug 24.
6
Therapeutic targeting of splicing in cancer.癌症中剪接的治疗靶向作用
Nat Med. 2016 Sep 7;22(9):976-86. doi: 10.1038/nm.4165.
7
Targeting splicing factors for cancer therapy.针对剪接因子的癌症治疗。
RNA. 2023 Apr;29(4):506-515. doi: 10.1261/rna.079585.123. Epub 2023 Jan 25.
8
Aberrant pre-mRNA processing in cancer.癌症中的异常前体 mRNA 处理。
J Exp Med. 2024 Nov 4;221(11). doi: 10.1084/jem.20230891. Epub 2024 Sep 24.
9
Pan-cancer analysis identifies mutations in that recapitulate mutant SF3B1 splicing dysregulation.泛癌症分析鉴定出的突变可重现突变 SF3B1 的剪接失调。
Proc Natl Acad Sci U S A. 2020 May 12;117(19):10305-10312. doi: 10.1073/pnas.1922622117. Epub 2020 Apr 24.
10
Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.癌症中的剪接调控异常：从机制理解到一类新的治疗靶点。
Sci China Life Sci. 2020 Apr;63(4):469-484. doi: 10.1007/s11427-019-1605-0. Epub 2020 Feb 17.
引用本文的文献
1
Genetic variants of LncRNA associated with splicing regulation and their impact on ovarian cancer development.与剪接调控相关的长链非编码RNA的遗传变异及其对卵巢癌发展的影响。
Funct Integr Genomics. 2025 Sep 2;25(1):185. doi: 10.1007/s10142-025-01687-x.
2
ALDH18A1 has carcinogenic functions and regulates alternative splicing events of DNA repair-related genes in esophageal carcinoma cells.醛脱氢酶18A1具有致癌功能，并调节食管癌细胞中DNA修复相关基因的可变剪接事件。
Sci Rep. 2025 Aug 7;15(1):28845. doi: 10.1038/s41598-025-08006-1.
3
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications.癌症中的RNA表观遗传学：当前认知与治疗意义
MedComm (2020). 2025 Aug 3;6(8):e70322. doi: 10.1002/mco2.70322. eCollection 2025 Aug.
4
Cas13d-mediated isoform-specific RNA knockdown with a unified computational and experimental toolbox.利用统一的计算和实验工具箱实现Cas13d介导的异构体特异性RNA敲低。
Nat Commun. 2025 Jul 29;16(1):6948. doi: 10.1038/s41467-025-62066-5.
5
Single cell and spatial alternative splicing analysis with Nanopore long read sequencing.利用纳米孔长读长测序进行单细胞和空间可变剪接分析。
Nat Commun. 2025 Jul 19;16(1):6654. doi: 10.1038/s41467-025-60902-2.
6
Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy.精准癌症免疫治疗新抗原发现中的计算策略与临床应用
Biomark Res. 2025 Jul 9;13(1):96. doi: 10.1186/s40364-025-00808-9.
7
RBM5 recruiting MGC32805 in a sandwich mode and inducing ΔFAS neoantigen and triggering FAS properties switch: implication in colorectal cancer.RBM5以夹心模式招募MGC32805，诱导ΔFAS新抗原并触发FAS特性转换：对结直肠癌的影响
Oncogene. 2025 Jun 26. doi: 10.1038/s41388-025-03390-4.
8
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab.对接受阿扎胞苷±度伐利尤单抗治疗的RNA剪接因子突变型急性髓系白血病和高危骨髓增生异常综合征的综合免疫图谱分析
Ther Adv Hematol. 2025 Jun 21;16:20406207251347344. doi: 10.1177/20406207251347344. eCollection 2025.
9
Splicing to keep splicing: A feedback system for cellular homeostasis and state transition.持续剪接以维持剪接：细胞内稳态与状态转变的反馈系统。
Clin Transl Med. 2025 Jun;15(6):e70369. doi: 10.1002/ctm2.70369.
10
Multi-Omics Analysis of Survival-Related Splicing Factors and Identifies CRNKL1 as a Therapeutic Target in Esophageal Cancer.生存相关剪接因子的多组学分析并确定CRNKL1为食管癌的治疗靶点。
Genes (Basel). 2025 Mar 27;16(4):379. doi: 10.3390/genes16040379.
本文引用的文献
1
PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2.重复区域体细胞突变的泛癌分析揭示了小核仁RNA U2中的复发性突变。
NPJ Genom Med. 2022 Mar 14;7(1):19. doi: 10.1038/s41525-022-00292-2.
2
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells.合成内含子使剪接因子突变依赖性靶向癌细胞成为可能。
Nat Biotechnol. 2022 Jul;40(7):1103-1113. doi: 10.1038/s41587-022-01224-2. Epub 2022 Mar 3.
3
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.无注释蛋白扩展了癌症中 MHC-I 限制的免疫肽组。
Nat Biotechnol. 2022 Feb;40(2):209-217. doi: 10.1038/s41587-021-01021-3. Epub 2021 Oct 18.
4
Identification of a small molecule splicing inhibitor targeting UHM domains.鉴定一种靶向 UHM 结构域的小分子剪接抑制剂。
FEBS J. 2022 Feb;289(3):682-698. doi: 10.1111/febs.16199. Epub 2021 Oct 4.
5
hnRNP A/B Proteins: An Encyclopedic Assessment of Their Roles in Homeostasis and Disease.异质性核糖核蛋白A/B：对其在体内稳态和疾病中作用的全面评估
Biology (Basel). 2021 Jul 24;10(8):712. doi: 10.3390/biology10080712.
6
Isoform Age - Splice Isoform Profiling Using Long-Read Technologies.使用长读长技术进行异构体年龄 - 剪接异构体分析
Front Mol Biosci. 2021 Aug 2;8:711733. doi: 10.3389/fmolb.2021.711733. eCollection 2021.
7
Regulated control of gene therapies by drug-induced splicing.药物诱导剪接调控基因治疗。
Nature. 2021 Aug;596(7871):291-295. doi: 10.1038/s41586-021-03770-2. Epub 2021 Jul 28.
8
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).随机 3 期临床试验：化疗联合或不联合 oblimersen 治疗老年 AML 患者：CALGB 10201（Alliance）。
Blood Adv. 2021 Jul 13;5(13):2775-2787. doi: 10.1182/bloodadvances.2021004233.
9
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.SF3B1 口服调节剂 H3B-8800 在髓系肿瘤中的 I 期首次人体剂量递增研究。
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.
10
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.药物调节 RNA 剪接增强抗肿瘤免疫。
Cell. 2021 Jul 22;184(15):4032-4047.e31. doi: 10.1016/j.cell.2021.05.038. Epub 2021 Jun 24.
Zotero 插件